Lin D Y, Liaw Y F, Lee T Y, Lai C M
Liver Unit, Chang Gung Memorial Hospital, Taipei, Taiwan, Republic of China.
Gastroenterology. 1988 Feb;94(2):453-6. doi: 10.1016/0016-5085(88)90436-2.
A randomized controlled trial of hepatic arterial embolization was conducted in 63 consecutive patients who had unresectable but still embolizable hepatocellular carcinoma. Patients were randomized into three groups. Patients in group 1 received multiple hepatic arterial embolizations; patients in group 2 were given hepatic arterial embolization once, followed by monthly chemotherapy with high doses of 5-fluorouracil; and patients in group 3 received only monthly chemotherapy with high doses of 5-fluorouracil. Complete response was achieved in only 1 patient who received multiple hepatic arterial embolizations. Partial responses were observed in 13 patients (61.9%) in group 1, 10 patients (47.6%) in group 2, and 2 patients (9.5%) in group 3. The survival rates of patients in group 1 at the end of the ninth, 12th, 15th, 18th, and 21st months were 53.2%, 42.2%, 42.2%, 42.2%, and 42.2%, respectively, which were not significantly different from those of patients in group 2 but were better than the survival rates of patients in group 3. The results suggest that hepatic arterial embolization is an effective palliative treatment that prolongs survival of patients with unresectable hepatocellular carcinoma.
对63例患有无法切除但仍可栓塞的肝细胞癌的连续患者进行了肝动脉栓塞的随机对照试验。患者被随机分为三组。第1组患者接受多次肝动脉栓塞；第2组患者接受一次肝动脉栓塞，随后每月接受高剂量5-氟尿嘧啶化疗；第3组患者仅每月接受高剂量5-氟尿嘧啶化疗。仅1例接受多次肝动脉栓塞的患者实现了完全缓解。第1组有13例患者（61.9%）出现部分缓解，第2组有10例患者（47.6%）出现部分缓解，第3组有2例患者（9.5%）出现部分缓解。第1组患者在第9、12、15、18和21个月末的生存率分别为53.2%、42.2%、42.2%、42.2%和42.2%，与第2组患者的生存率无显著差异，但优于第3组患者的生存率。结果表明，肝动脉栓塞是一种有效的姑息治疗方法，可延长无法切除的肝细胞癌患者的生存期。
